Kiniksa Pharmaceuticals International Plc [KNSA] stock prices are up 0.51% to $19.70 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KNSA shares have gain 5.12% over the last week, with a monthly amount drifted -1.15%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on September 13, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $40. Previously, Wells Fargo started tracking the stock with Overweight rating on May 03, 2024, and set its price target to $34. On June 29, 2020, BofA Securities reiterated its Buy rating and revised its price target to $40 on the stock. BofA/Merrill started tracking the stock assigning a Buy rating and suggested a price target of $25 on April 01, 2020. Barclays initiated its recommendation with a Overweight and recommended $26 as its price target on March 11, 2019. Wedbush reiterated a Outperform rating for this stock on December 12, 2018, and upped its price target to $33. In a note dated June 19, 2018, JMP Securities initiated an Mkt Outperform rating and provided a target price of $33 on this stock.
The stock price of Kiniksa Pharmaceuticals International Plc [KNSA] has been fluctuating between $16.56 and $28.15 over the past year. Currently, Wall Street analysts expect the stock to reach $37.5 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $19.70 at the most recent close of the market. An investor can expect a potential return of 90.36% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
The Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] reported sales of 384.10M for trailing twelve months, representing a surge of 67.37%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.63 points at the first support level, and at 17.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.26, and for the 2nd resistance point, it is at 20.82.
Ratios To Look Out For
It’s worth pointing out that Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA]’s Current Ratio is 3.24. As well, the Quick Ratio is 2.95, while the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 3.70, the price to book ratio is 3.25.
Transactions by insiders
Recent insider trading involved Tessari Eben, Officer, that happened on Feb 10 ’25 when 14000.0 shares were purchased. CHIEF OPERATING OFFICER, Tessari Eben completed a deal on Jan 13 ’25 to sell 14000.0 shares. Meanwhile, Officer Tessari Eben bought 14000.0 shares on Jan 13 ’25.
